Literature DB >> 27509835

DNA sequence analysis in 598 individuals with a clinical diagnosis of osteogenesis imperfecta: diagnostic yield and mutation spectrum.

G Bardai1, P Moffatt1, F H Glorieux1, F Rauch2.   

Abstract

We detected disease-causing mutations in 585 of 598 individuals (98 %) with typical features of osteogenesis imperfecta (OI). In mild OI, only collagen type I encoding genes were involved. In moderate to severe OI, mutations in 12 different genes were found; 11 % of these patients had mutations in recessive genes.
INTRODUCTION: OI is usually caused by mutations in COL1A1 or COL1A2, the genes encoding collagen type I alpha chains, but mutations in at least 16 other genes have also been associated with OI. It is presently unknown what proportion of individuals with clinical features of OI has a disease-causing mutation in one of these genes.
METHODS: DNA sequence analysis was performed on 598 individuals from 487 families who had a typical OI phenotype. OI type I was diagnosed in 43 % of individuals, and 57 % had moderate to severe OI, defined as OI types other than type I.
RESULTS: Disease-causing variants were detected in 97 % of individuals with OI type I and in 99 % of patients with moderate to severe OI. All mutations found in OI type I were dominant and exclusively affected COL1A1 or COL1A2. In moderate to severe OI, dominant mutations were found in COL1A1/COL1A2 (77 %), IFITM5 (9 %), and P4HB (0.6 %). Mutations in one of the recessive OI-associated gene were observed in 12 % of individuals with moderate to severe OI. The genes most frequently involved in recessive OI were SERPINF1 (4.0 % of individuals with moderate to severe OI) and CRTAP (2.9 %).
CONCLUSIONS: DNA sequence analysis of currently known OI-associated genes identifies disease-causing variants in almost all individuals with a typical OI phenotype. About 20 % of individuals with moderate to severe OI had mutations in genes other than COL1A1/COL1A2.

Entities:  

Keywords:  Children; Fractures; Mutations; Next-generation sequencing; Osteogenesis imperfecta

Mesh:

Substances:

Year:  2016        PMID: 27509835     DOI: 10.1007/s00198-016-3709-1

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI.

Authors:  Frank Rauch; Abdallah Husseini; Peter Roughley; Francis H Glorieux; Pierre Moffatt
Journal:  J Clin Endocrinol Metab       Date:  2012-06-05       Impact factor: 5.958

2.  Altered triple helical structure of type I procollagen in lethal perinatal osteogenesis imperfecta.

Authors:  J Bonadio; K A Holbrook; R E Gelinas; J Jacob; P H Byers
Journal:  J Biol Chem       Date:  1985-02-10       Impact factor: 5.157

3.  Osteogenesis Imperfecta Type I Caused by COL1A1 Deletions.

Authors:  Ghalib Bardai; Emmanuelle Lemyre; Pierre Moffatt; Telma Palomo; Francis H Glorieux; Joanna Tung; Leanne Ward; Frank Rauch
Journal:  Calcif Tissue Int       Date:  2016-01       Impact factor: 4.333

4.  Cole-Carpenter syndrome is caused by a heterozygous missense mutation in P4HB.

Authors:  Frank Rauch; Somayyeh Fahiminiya; Jacek Majewski; Jian Carrot-Zhang; Sergei Boudko; Francis Glorieux; John S Mort; Hans-Peter Bächinger; Pierre Moffatt
Journal:  Am J Hum Genet       Date:  2015-02-12       Impact factor: 11.025

5.  Osteoporosis caused by mutations in PLS3: clinical and bone tissue characteristics.

Authors:  Somayyeh Fahiminiya; Jacek Majewski; Hadil Al-Jallad; Pierre Moffatt; John Mort; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Frank Rauch
Journal:  J Bone Miner Res       Date:  2014-08       Impact factor: 6.741

6.  Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients.

Authors:  Frank Rauch; Pierre Moffatt; Moira Cheung; Peter Roughley; Liljana Lalic; Allan M Lund; Norman Ramirez; Somayyeh Fahiminiya; Jacek Majewski; Francis H Glorieux
Journal:  J Med Genet       Date:  2013-01       Impact factor: 6.318

Review 7.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

8.  Targeted sequencing of a pediatric metabolic bone gene panel using a desktop semiconductor next-generation sequencer.

Authors:  Frank Rauch; Liljana Lalic; Francis H Glorieux; Pierre Moffatt; Peter Roughley
Journal:  Calcif Tissue Int       Date:  2014-08-03       Impact factor: 4.333

9.  Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease.

Authors:  L M Ward; F Rauch; R Travers; G Chabot; E M Azouz; L Lalic; P J Roughley; F H Glorieux
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

10.  EMQN best practice guidelines for the laboratory diagnosis of osteogenesis imperfecta.

Authors:  Fleur S van Dijk; Peter H Byers; Raymond Dalgleish; Fransiska Malfait; Alessandra Maugeri; Marianne Rohrbach; Sofie Symoens; Erik A Sistermans; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2011-08-10       Impact factor: 4.246

View more
  44 in total

Review 1.  Bone Disease in Patients with Ehlers-Danlos Syndromes.

Authors:  Shuaa Basalom; Frank Rauch
Journal:  Curr Osteoporos Rep       Date:  2020-04       Impact factor: 5.096

2.  ALPL mutations in adults with rheumatologic disorders and low serum alkaline phosphatase activity.

Authors:  Frank Rauch; Ghalib Bardai; Cheryl Rockman-Greenberg
Journal:  J Bone Miner Metab       Date:  2019-02-04       Impact factor: 2.626

Review 3.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

4.  Osteogenesis imperfecta type III/Ehlers-Danlos overlap syndrome in a Chinese man.

Authors:  Yanqin Lu; Yanzhou Wang; Frank Rauch; Hu Li; Yao Zhang; Naixiang Zhai; Jian Zhang; Xiuzhi Ren; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-02

Review 5.  Osteogenesis imperfecta: an update on clinical features and therapies.

Authors:  Ronit Marom; Brien M Rabenhorst; Roy Morello
Journal:  Eur J Endocrinol       Date:  2020-10       Impact factor: 6.664

6.  Pulmonary and diaphragmatic pathology in collagen type I α1 mutant mice with osteogenesis imperfecta.

Authors:  Carolyn J Baglole; Feng Liang; Hussein Traboulsi; Angela Rico de Souza; Christian Giordano; Josephine T Tauer; Frank Rauch; Basil J Petrof
Journal:  Pediatr Res       Date:  2018-05-09       Impact factor: 3.756

7.  Molecular diagnosis in children with fractures but no extraskeletal signs of osteogenesis imperfecta.

Authors:  G Bardai; L M Ward; P Trejo; P Moffatt; F H Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2017-04-04       Impact factor: 4.507

8.  Long-term follow-up in osteogenesis imperfecta type VI.

Authors:  P Trejo; T Palomo; K Montpetit; F Fassier; A Sato; F H Glorieux; F Rauch
Journal:  Osteoporos Int       Date:  2017-07-09       Impact factor: 4.507

9.  Gene mutation spectrum and genotype-phenotype correlation in a cohort of Chinese osteogenesis imperfecta patients revealed by targeted next generation sequencing.

Authors:  Y Liu; D Ma; F Lv; X Xu; J Wang; W Xia; Y Jiang; O Wang; X Xing; W Yu; J Wang; J Sun; L Song; Y Zhu; H Yang; J Wang; M Li
Journal:  Osteoporos Int       Date:  2017-07-19       Impact factor: 4.507

10.  Complex heterozygous WNT1 mutation in severe recessive osteogenesis imperfecta of a Chinese patient.

Authors:  Yanqin Lu; Yunzhang Dai; Yanzhou Wang; Naixiang Zhai; Jian Zhang; Junlong Liu; Xiaoli Yin; Tianyou Li; Xiuzhi Ren; Jinxiang Han
Journal:  Intractable Rare Dis Res       Date:  2018-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.